Phase I Clinical Trial Evaluating Safety, Tolerability, and Early Activity of Exarafenib (KIN-2787), a Highly Selective Pan-RAF Inhibitor, in BRAF-Altered Solid Tumors or NRAS-Mutant Melanoma PD-L1 ...

Skin cancers, lung cancers, lymphomas—though these cancers affect different parts of the body, they can all be treated with one of the latest therapies medicine has to offer: checkpoint inhibitors.

(A) Presence of PD-1, its ligands PD-L1 and PD-L2, and the phosphatases SHP-1, SHP-2, and SHP-2-like (SHP-2L) in representative jawed vertebrates, including sharks, ray-finned fish, amphibians, and ...

Leveraging AI-Driven Multiomics and Spatial Biology to Unlock the Full Potential of Next-Generation Cytotoxic Dual Checkpoint InhibitorWALTHAM, Mass. & HOUSTON--(BUSINESS WIRE)--BostonGene, developer ...